Jefferies Names Possible Hedge Fund Short Targets

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. DSX
2. GNK
3. INTC
4. SPCX
5. III
6. TTEC
7. DAL
8. AWK
9. GZDIF
10. ATNI

Go back to Jefferies Names Possible Hedge Fund Short Targets

Biogen (BIIB) Reports FDA Approval of PLEGRIDY (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis

February 1, 2021 7:33 AM EST

Biogen Inc. (NASDAQ: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved a new intramuscular (IM) injection route of administration for PLEGRIDY® (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS). The new IM administration offers people living with relapsing MS the well-characterized efficacy and safety of PLEGRIDY with the potential for significantly reduced injection site reactions. This... More

RBC Capital Reiterates Sector Perform Rating on Pfizer (PFE)

February 1, 2021 6:49 AM EST

RBC Capital analyst Randall Stanicky reiterated a Sector Perform rating and $42.00 price target on Pfizer (NYSE: PFE) ahead of the company's 4Q earnings release. PFE is set to report 4Q results this Tuesday. Stanicky thinks the 4Q set up is relatively favorable on the back... More

Stifel Upgrades Biogen (BIIB) to Buy

January 29, 2021 8:48 AM EST

Stifel analyst Paul Matteis upgraded Biogen (NASDAQ: BIIB) from Hold to Buy with a price target of $358.00 (from $258.00).

The analyst comments "Our initial reaction after the Aducanumab AdComm was that the path to FDA approval seems challenging. Since, Biogen management's... More